Aignostics and Bayer to Present on Joint Target ID Platform at ESMO AI
Companies to highlight collaboration progress, including expansion to an additional indication
Aignostics and Bayer will co-present initial outcomes from their strategic partnership at the upcoming ESMO AI conference. This presentation will describe findings from their research collaboration to jointly develop a target discovery platform, with the ultimate objective of identifying novel cancer targets. The platform was built to enable scalable, modular exploration of cancer biology and leverages data, technology, and expertise from both organizations. The presentation will also highlight advancements in the Aignostics-Bayer partnership more broadly, including its expansion to an additional indication in oncology.
"Our joint presentation at ESMO AI showcases how we are combining Bayer's expertise in oncology Precision Drug Discovery with Aignostics' computational capabilities to shape innovation for target discovery," said Emmanuelle di Tomaso, Global Head Translational Sciences Oncology at Bayer. "This partnership is an important part of our broader efforts to drive digital innovation in drug discovery, and we're pleased with the progress we're making together."
"Presenting alongside Bayer at ESMO AI represents a meaningful milestone in our collaboration," said Viktor Matyas, CEO of Aignostics. "Our work together is advancing a new approach to target discovery that integrates computational methods with multimodal data and clinical insights. As we continue to develop our platform, we anticipate uncovering new opportunities to improve outcomes for cancer patients."
About Aignostics
Aignostics is an artificial intelligence company that turns complex pathology data into transformative insights. By combining proprietary access to multimodal clinical data, industry-leading technologies, and rigorous science, Aignostics develops best-in-class products and services for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development. Aignostics’ latest product, Atlas H&E-TME, is a self-service application for comprehensive tumor microenvironment profiling in H&E images at single-cell resolution, empowering researchers with unprecedented precision and scalability. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading investors and has operations in Berlin and New York.
More information at: www.aignostics.com
Follow us on LinkedIn: www.linkedin.com/company/aignostics